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Background: QuantiFERON-TB Gold in-tube (QFT-GIT) is an interferon-
gamma release assay (IGRA) used to diagnose latent tuberculosis 
infection. Limited data exists on performance of QuantiFERON-TB 
Gold-Plus (QFT-Plus), a next generation of IGRA that includes an 
additional antigen tube 2 (TB2) while excluding TB7.7 from antigen 
tube 1 (TB1), to measure TB specific CD4+ and CD8+ T lymphocytes 
responses. We compared the performance of QFT-Plus with QFT-GIT 
among highly TB exposed goldminers in South Africa. 
Methods: We enrolled HIV-negative goldminers in South Africa, ≥33 
years with no prior history of TB disease or evidence of silicosis. Blood 
samples were collected for QFT-GIT and QFT-Plus. QFT-GIT was 
considered positive if TB1 tested positive; while QFT-Plus was positive 
if both or either TB1 or TB2 tested positive, as per manufacturer's 
recommendations. We compared the performance of QFT-Plus with 
QFT-GIT using Cohen’s Kappa. To assess the specific contribution of 
CD8+ T-cells, we used TB2−TB1 differential values as an indirect 
estimate. A cut-off value was set at 0.6. Logistic regression was used to 
identify factors associated with having TB2-TB1>0.6 difference on QFT-
Plus. 
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Results: Of 349 enrolled participants, 304 had QFT-Plus and QFT-GIT 
results: 205 (68%) were positive on both assays; 83 (27%) were 
negative on both assays while 16 (5%) had discordant results. Overall, 
there was 94.7% (288/304) agreement between QFT-Plus and QFT-GIT 
(Kappa = 0.87). 214 had positive QFT-Plus result, of whom 202 [94.4%, 
median interquartile range (IQR): 3.06 (1.31, 7.00)] were positive on 
TB1 and 205 [95.8%, median (IQR): 3.25 (1.53, 8.02)] were positive on 
TB2. A TB2-TB1>0.6 difference was observed in 16.4% (35/214), with 
some evidence of a difference by BMI; 14.9% (7/47), 9.8% (9/92) and 
25.3% (19/75) for BMI of 18.5-24.9, 18.5-25 and >30 kg/m2, 
respectively (P=0.03). 
Conclusion: In a population of HIV-negative goldminers, QFT-Plus 
showed a similar performance to QFT-GIT.
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Introduction
Latent tuberculosis infection (LTBI) is the seedbed from 
which tuberculosis (TB) cases arise. LTBI is defined as an 
asymptomatic state characterized with a persistent immune 
response to stimulation by Mycobacterium tuberculosis (Mtb) 
antigens with no evidence of active TB1–3. LTBI is typically 
characterized by a positive tuberculin skin test (TST) in vivo, 
involving intradermal injection of purified protein derivative 
from Mtb strain and/or a positive interferon-gamma release 
assay (IGRA)4,5. Better tests are needed to identify persons at 
increased risk of developing TB disease.
IGRAs measure released interferon-gamma from cluster of dif-
ferentiation (CD) T-lymphocytes specific to Mtb complex 
antigens but not produced by Mycobacterium bovis BCG vac-
cine strains6. QuantiFERON-TB Gold In-Tube assay (QFT-GIT) 
is designed to elicit interferon-gamma response from CD4+ 
helper T lymphocytes in a single TB antigen tube contain-
ing long peptides from ESAT-6, CPF-10 and TB7.7 antigens 
(Qiagen, Germantown, MD)5–7. QuantiFERON-TB Gold Plus 
assay (QFT-Plus) is a next generation IGRA that contains 
peptides from only the ESAT-6 and CFP-10 antigens comprising 
a TB1 tube, identical to the QFT-GIT, with the exception 
of TB7.7, and stimulates CD4+ T cells, and an additional 
antigen tube, TB2, which has a cocktail of both long and short 
ESAT-6 and CFP-10 peptides to elicit interferon-gamma release 
from both CD4+ helper T lymphocytes and CD8+ cytotoxic 
T lymphocytes5–8.
CD8+ cytotoxic T lymphocytes stimulating peptide was 
included in the QFT-Plus assay to improve on the sensitivity of 
QFT-GIT. Currently, limited data exist comparing the per-
formance of these assays in high TB burdened settings. We 
compared the performance of QFT-Plus with QFT-GIT among 
highly Mtb exposed goldminers in South Africa.
Methods
Study setting and population
The study was conducted in the South African goldmines at the 
Occupational Health Centre (OHC), in Orkney, North West 
Province among goldminers, attending for their annual medical 
examination between July 2015 and December 2016.
Study design and procedures – parent study
In a cohort study, herein described as the parent study, we 
enrolled miners to identify those who were uninfected with Mtb 
despite being highly exposed to Mtb, to compare epidemio-
logical factors between Mtb uninfected and infected miners and 
to collect specimens from Mtb uninfected and infected min-
ers to determine gene expression and immunological profiles 
associated with being Mtb uninfected in future analysis.
Goldminers, attending OHC for their annual medical exami-
nation were pre-screened for the study to identify those aged 
33-60 years who had worked in the mining industry for at least 
15 years. Following informed consent, a full screen was con-
ducted. Miners were included if they did not have symptoms 
suggestive of TB, no prior or current history of treatment 
for active TB disease, no history of or not currently taking iso-
niazid preventive therapy, no silicosis, had body mass index 
(BMI) >18.5, no serious medical conditions, HIV negative 
and no current treatment for cancer, no treatment with steroid 
tablets, inhalers or injections.
Blood samples were collected intravenously by trained 
professional phlebotomy nurses amongst those who met the 
inclusion criteria for QFT (QFT-Plus and QFT-GIT; Qiagen, 
Hilden Germany), peripheral blood mononuclear cell (PBMC), 
and transcriptomic (PAXgene) testing. Under the first version 
of the protocol (enrolments from 10 July 2015 to 29 October 
2015), participants gave blood samples for QFT at enrolment 
and were followed up at 90 days where QFT was repeated and 
TST (RT-23 in Tween-80, Statens Serum Institute, Copenha-
gen, Denmark, catalogue numbers: XI1177KL and SP18411C) 
was placed and read by a professional nurses who were trained 
in placing and reading TST. The protocol was subsequently 
simplified and under the second version (enrolments after 29 
October 2015) participants gave blood samples for QFT at 
enrolment and TST placed either at enrolment or seven days 
later. All participants, regardless of protocol version, were 
followed up to 12 months where QFT and TST were 
 repeated.
A sputum sample was also collected for mycobacterial culture 
testing (BACTEC MGIT 960 system, BD Diagnostic Systems, 
Sparks, MD, USA) to exclude subclinical TB. A questionnaire 
was administered in a private room by a trained research 
assistant to collect demographic characteristics and informa-
tion on factors associated with being TB uninfected. Blood 
samples collected were tested at the Aurum Clinical Research 
laboratory for LTBI using QFT-GIT and QFT-Plus. A 6 ml of 
whole blood sample was collected intravenously from each par-
ticipant into a single lithium heparin tube. Samples were then 
transported to Aurum Clinical Research laboratory where they 
were aliquoted into 1 ml tubes: three tubes for QFT-GIT test kit 
(QFT-GIT nil, QFT-GIT TB, QFT-GIT mitogen with catalogue 
numbers 0594-0201 and 0594-0501) and four for QFT-Plus 
(QFT-Plus nil, QFT-Plus TB1, QFT-Plus TB2, QFT-Plus 
mitogen with catalogue number 622120). Tubes were then 
placed in a pre-heated 37°C portable incubator for 16-24 hours, 
within eight hours of collection. Subsequently, samples were 
centrifuged to separate plasma for same day testing. Alter-
natively, samples were stored at -80°C for up to 48-72 
hours prior testing. Plasma was tested by interferon-gamma 
enzyme-linked immunosorbent assay (ELISA), performed using 
Biotek microplate reader model EL x 800 using Gen 5 soft-
ware. Biotek microplate washer model EL x 508 and Thermostar 
shaker were also used.
Study design – sub-study
In this sub-study, using cross-sectional data from the par-
ent study, we compared the performance of QFT-Plus with 
QFT-GIT using QFT and TST measurements all done either at 
baseline/seven days (participants enrolled under the 2nd version 
of protocol) or at 90 days post-enrolment (participants enrolled 
under the 1st version of protocol).
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Study definitions
QFT-GIT was considered positive if TB1 tested positive; while 
QFT-Plus was positive if both TB1 and TB2 tested positive 
or if either TB1 or TB2 tested positive, as per manufacturer’s 
recommendations. TST induration ≥5mm was considered posi-
tive. To assess the specific contribution of CD8+ T-cells, we 
used TB2−TB1 differential values as an indirect estimate. A 
cut-off value was set at 0.6 in order to reduce the bias of the 
intrinsic variability of the test9.
Statistical methods
All eligible participants from the parent study were included in 
the analysis. Binary outcomes (positive/negative) from QFT-
Plus and QFT-GIT were compared using the percentage agree-
ment and Kappa statistic. TB1 and TB2 responses for those 
QFT-Plus positive were summarized by QFT-GIT status using 
median and interquartile range (IQR) and percentage posi-
tive (measurement minus nil response>0.35). TST positivity 
was summarized by QFT-Plus status. Logistic regression was 
used to identify factors associated with having TB2-TB1 >0.6. 
Results were summarized using odds ratios (OR) with their 
corresponding 95% confidence intervals (CI) and p-values. 
Due to a small number of outcomes a multivariable analysis 
was not conducted. Data were analyzed using Stata version 15 
(StataCorp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LP.
Ethical statement
The study received ethical clearance from the University of 
Witwatersrand Human Research Ethics Committee (WHREC 
Ref: 150217), London School of Hygiene & Tropical Medi-
cine, UK (LSHTM Ethics Ref: 9279), University of Washington, 
USA (IRB number 33335) and North West Health Research 
and Ethics Committee (DOH-27-0515-4991). We sought informed 
consent from all study participants using written informed con-
sent and information sheets available in the most commonly 
used local languages. Participants who were unable to read or 
write were asked to make a mark or thumbprint in the pres-
ence of a witness. This study was conducted according to 
Good Clinical Practice guidelines, in accordance with the 
requirements of the funders and respective ethics committees.
Results
Process flow
We approached 25,627 miners, 17,030 (66.5%) agreed to be 
pre-screened, of whom 3,534 (20.8%) satisfied the pre-screen 
criteria and were eligible for full screening, following informed 
consent (Figure 1). Overall, 2,980 (84.3%) were offered con-
sent, of whom 1,749 (58.7%) consented and 1,231 (41.3%) 
declined to take part in the study; 554 (15.7%) were not 
offered consent as they were lost in the OHC queue.
Following the full screen, 349/1749 (20.0%) met the inclu-
sion criteria and were enrolled into the study. Of the 349, 304 
had a baseline QFT-Plus and QFT-GIT while 234 had QFT-GIT, 
QFT-Plus and TST measured within seven days of each other. 
For the latter, which is restricted to having a TST measurement 
within seven days of the QFT measurements, participants 
enrolled under the 1st version of the protocol contribute 
QFT-Plus and QFT-GIT measurements from their 90-day visit.
Demographic characteristics
Of the 349 participants enrolled into the study, the median age 
was 48 years (IQR 45, 53 years), median years in the work-
face was 24 (IQR 18, 28 years) and 98.6% (344) were male 
(Table 1). Overall, 92.0% (321) were of Black/African ethnic-
ity, 72.5% (253) had a BCG scar present, 66.8% (233) were 
born in South Africa and a minority lived in a mine hostel 
(28.7%; 100). Subsamples of the 349 participants who either 
had (i) a baseline QFT-Plus and QFT-GIT result (n=304) or (ii) 
QFT-Plus and TST reading (n=234) had similar demographic 
characteristics to the overall sample10.
Comparison of QuantiFERON-TB Gold-Plus vs. Gold 
in-tube
Of the 304 who had QFT-Plus and QFT-GIT results, 214 (70.4%) 
had a positive QFT-Plus result, 205 (67.4%) were positive 
on both assays; 83 (27.3%) were negative on both assays, while 
16 (5.3%) had discordant results (seven QFT-Plus negative/
QFT-GIT positive; nine QFT-Plus positive/QFT-GIT negative) 
(Table 2). Overall, the agreement between QFT-Plus and 
QFT-GIT was 94.7% (288/304) and Kappa was 0.87.
Two hundred and thirty-four participants had QFT-Plus, 
QFT-GIT and TST measured at the same time/or within seven 
days of each other. Overall, 54.7% (128) had a TST response 
≥5mm, 11.1% (26) had a TST response >0mm and <5mm and 
34.2% (80) had zero TST response. The median TST response 
was 11mm (IQR 6-15mm), among those with a TST>0mm. Of 
the 234, 160 (68.4%) were positive on both assays, of whom 
61.3% (98/160) were TST-positive, and 62 (26.5%) were nega-
tive on both assays, of whom 40.3% (25/62) TST-positive. 
Furthermore, 101 (43.2%) were QFT-Plus positive/TST posi-
tive; 41 (17.5%) were QFT-Plus negative/TST negative; 65 
(27.8%) were QFT-Plus positive/TST negative; and 27 (11.5%) 
were QFT-Plus negative/TST positive. However, 12 (5.1%) 
had discordant results [six QFT-GIT positive/QFT-Plus nega-
tive, 33.3% (2/6) TST positive; six QFT-GIT negative/QFT-Plus 
positive, 50.0% (3/6) TST positive]. When analysis was restricted 
to a subsample of 234, the percentage agreement between 
QFT-GIT and QFT-Plus was 94.9%, similar to before.
Assessing the specific contribution of CD8+ T-cells
Of the 214 who had positive QFT-Plus results, 202 (94.4%) 
were positive on TB1, while 205 (95.8%) were positive on 
TB2 (Table 2). The median (IQR) values for TB1 and TB2 
among those who were QFT-Plus positive were 3.06 (1.31, 7.00) 
and 3.25 (1.53, 8.02), respectively. The median difference 
between the TB1 and TB2 was 0.00 (-0.17, 0.39). A >0.6 differ-
ence between TB2 and TB1 was observed in 16.4% (35/214) of 
those who were positive on QFT-Plus (Table 2). Only BMI 
status was found to be associated with TB2-TB1 >0.6; unad-
justed OR 1.94 (95% CI: 0.74–5.05) for BMI>30 kg/m2 versus 
BMI between 18.5-24.9 (Table 3).
Page 4 of 12
Gates Open Research 2021, 5:66 Last updated: 04 JUN 2021
Discussion
In this study, conducted in South African goldmines, the over-
all agreement between QFT-Plus and QFT-GIT was high at 
94.7%, suggesting that QFT-GIT may have similar performance 
to QFT-Plus; consistent with previous evaluation studies con-
ducted in low TB incidence settings which showed similar 
diagnostic performance and high overall agreement between 
QFT-Plus and its predecessor5,8,11–15. The high concordance 
Figure 1. Participant flow chart at enrolment. *Data from the daily attendance register. Includes repeat attendances during this 
time period. §Screen out questions were asked in stages; if screened out at a stage no screening was conducted for subsequent stages. 
Within a stage more than one screen-out reason may apply. Yrs, years; IPT, isoniazid preventive therapy; BMI, body mass index; QFT-Plus, 
QuantiFERON-TB Gold-Plus; QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TST, tuberculin skin test.
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(or low discordance) in our study may be because our study 
was in HIV negative adults among whom QFT-GIT would be 
expected to have relatively high sensitivity. A greater difference 
between the two tests might be expected in populations where 
QFT-GIT typically has poor sensitivity e.g. children and peo-
ple with advanced HIV disease11,16–18. Overall, there were 16 dis-
cordant pairs (5.3%); seven were QFT-Plus negative/QFT-GIT 
positive and nine were QFT-Plus positive/QFT-GIT negative. It 
is interesting that only 56.3% were QFT-Plus positive/QFT-GIT 
negative and not higher. The discordancy rate found in our study 
was consistent with findings from Theel et al. and Moon et al. 
studies, which showed discordancy rates of 3.1% and 4.4%, 
respectively5,12. However, of the five discordant pairs in the 
Theel et al. study, 60.0% (3/5) were QFT-Plus negative/QFT-
GIT positive and 40.0% (2/5) were QFT-Plus positive/QFT-GIT 
negative; while in the Moon et al. study, 25.6% (11/43) were 
QFT-Plus negative/QFT-GIT positive and 74.4% (32/43) were 
QFT-Plus positive/QFT-GIT negative in the 43 discordant pairs. 
This is thought to be due to several factors, broadly classi-
fied as preanalytical, analytical, postanalytical, manufacturing, 
immunological, and interferon-gamma levels bordering on the 
binary 0.35 IU/ml cutoff for assay positivity9,19–21.
We observed a TB2−TB1 difference >0.6 among 35 (16.4%) 
individuals who had QFT-Plus positive results, associated 
with obesity. Barcellini et al. had also observed a similar 
TB2−TB1 difference >0.6 in a small proportion of TB con-
tacts who had a positive QFT-Plus results 18 (15.1%); suggest-
ing presence of Mtb-specific CD8+ T lymphocytes, which may 
be indicative of a higher antigenic burden14,22–27. The presence of 




a QFT-Plus and 
QFT-GIT result
Participants 
enrolled with a 
QFT-Plus, QFT-GIT 
& TST result
N 349 304 234
Age, years Median (IQR) 48 (45-52) 48 (44-52) 48.5 (44-52)
Sex Male 344 (98.6%) 300 (98.7%) 230 (98.3%)
BCG scar No 84 (24.1%) 74 (24.3%) 58 (24.8%)
Yes 253 (72.5%) 221 (72.7%) 171 (73.1%)
Indeterminate 12 (3.4%) 9 (3.0%) 5 (2.1%)
Country of birth South Africa 233 (66.8%) 204 (67.1%) 157 (67.1%)
Lesotho 59 (16.9%) 50 (16.4%) 38 (16.2%)
Mozambique 37 (10.6%) 32 (10.5%) 26 (11.1%)
Other 20 (5.7%) 18 (5.9%) 13 (5.6%)
Ethnicity Black/African 321 (92.0%) 279 (91.8%) 218 (93.2%)
Hostel No 170 (48.7%) 155 (51.0%) 122 (52.1%)
Hostel 100 (28.7%) 83 (27.3%) 58 (24.8%)
Other mine house 79 (22.6%) 66 (21.7%) 54 (23.1%)
Years worked 
underground Median (IQR) 24 (18-28) 24 (17.5-28) 24 (17-28)
Sleeping 
arrangement Alone 51 (14.6%) 46 (15.1%) 34 (14.5%)
1 person 206 (59.0%) 182 (59.9%) 139 (59.4%)
> 1 person 92 (26.4%) 76 (25.0%) 61 (26.1%)
Occupation Unskilled 271 (77.7%) 236 (77.6%) 188 (80.3%)
IQR, interquartile range; QFT-Plus, QuantiFERON-TB Gold-Plus; QFT-GIT, QuantiFERON-TB Gold; TST, tuberculin 
skin test.
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Mtb-specific CD8+ T lymphocytes in latently infected 
miners may therefore be predictive of Mtb active replica-
tion and may be indicative of higher likelihood of disease 
progression23.
Study limitations
This sub-analysis was based on a cross-sectional sample and 
did not include follow-up to confirm the LTBI status. How-
ever, in this population of goldminers with long duration of 
service, equating to prolonged exposure to Mtb infection, it is 
unlikely that the LTBI status would change over a relatively 
short period of follow-up. The sample size of 304 was rela-
tively small to make strong inferences. In addition, the study 
was conducted among HIV-negative goldminers, selected for 
those most likely to have experienced Mtb exposure, thus the 
results may not be generalizable. The lack of a gold-standard 
test for Mtb infection means that where results were discordant, 
we cannot know which (if either) was correct.
Table 2. Comparison of QuantiFERON-TB Gold-Plus vs. QuantiFERON-TB Gold in-tube.
Participants who have QFT-Plus and QFT-GIT, TST data not shown
QFT-GIT N



























































Participants who have QFT-Plus, QFT-GIT and a TST measurement within seven days of the QFT results
QFT-GIT N




















Positive 166 1601 62




































^ n=304 who have QFT-Plus and QFT-GIT. Percentage agreement 94.7% (95%CI: 91.6– 97.0%); Kappa 0.87.
^^ n=234/304 who have QFT-Plus and QFT-GIT and a TST measurement within seven days of the QFT results. For participants enrolled under the 1st 
version of the protocol the QFT-Plus and QFT-GIT measurements are from the 90-day visit. Percentage agreement 94.9% (95%CI: 91.2 – 97.3%); Kappa 
0.88.
1 61.3% [98/160] TST positive (defined as ≥5mm); 2 33.3% [2/6] TST positive; 3 50.0% [3/6] TST positive; 4 40.3% [25/62] TST positive.
a Of the 198, n=5 are positive on TB1 alone; b of the 200, n=7 are positive on TB2 alone; c of the four, all are positive on TB1 alone; d of the five, all are 
positive on TB2 alone.
e Of the 154, n=3 are positive on TB1 alone; f of the 157, n=6 are positive on TB2 alone; g of the three, all are positive on TB1 alone; h of the three, all are 
positive on TB2 alone.
* Defined as TB1-nil>0.35 or TB2-nil>0.35.
QFT-Plus, QuantiFERON-TB Gold-Plus; QFT-GIT, QuantiFERON-TB Gold in-tube; IQR interquartile range; CI confidence interval.
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Table 3. Risk factors for having TB2-TB1>0.6 on QFT-plus.
Variable N TB2-TB1 >0.6 n (%)
Univariable analysis
Crude 
OR 95% CI p-value*
Age group, years 0.85
<45 48 7 (14.6) 1
45–49 71 13 (18.3) 1.31 0.48 - 3.58
≥50 95 15 (15.8) 1.10 0.42 - 2.91
Gender 0.66
Male 210 34 (16.2) 1
Female 4 1 (25.0) 1.73 0.17 - 17.09
Ethnicity 0.20
Black/African 209 33 (15.8) 1
Other 5 2 (40.0) 3.56 0.57 - 22.11
Marital status 0.14
Married 193 29 (15.0) 1
Other 21 6 (28.6) 2.26 0.81 - 6.31
Country of birth 0.85
South Africa 141 25 (17.7) 1
Lesotho 39 5 (12.8) 0.68 0.24 - 1.92
Mozambique 23 3 (13.0) 0.70 0.19 - 2.52
Other 11 2 (18.2) 1.03 0.21 - 5.07
Occupational level 0.17
Unskilled 177 26 (14.7) 1
Skilled 37 9 (24.3) 1.87 0.79-4.41
Years worked underground 0.99
<20 61 10 (16.4) 1
20-29 112 18 (16.1) 0.98 0.42 - 2.27
≥30 41 7 (17.1) 1.05 0.36 - 3.03
Type of mine housing 0.31
Not staying in mine house 102 17 (16.7) 1
Hostel 68 8 (11.8) 0.67 0.27 - 1.64
Other mine housing 44 10 (22.7) 1.47 0.61 - 3.53
Sleeping arrangement 0.30
Alone 38 5 (13.2) 1
1 person 129 25 (19.4) 1.59 0.56 - 4.48
>1 person 47 5 (10.6) 0.79 0.21 - 2.94
Page 8 of 12
Gates Open Research 2021, 5:66 Last updated: 04 JUN 2021
Conclusion
Among HIV-negative goldminers in South Africa, the perform-
ance of QFT-Plus was similar to QFT-GIT. For most discordant 
results, interferon-gamma concentrations bordered on the binary 
cutoff for assay positivity.
Data availability
LSHTM Data Compass: Data set for the comparison of the 
performance of QuantiFERON-TB Gold Plus with QuantiF-
ERON-T Gold in-tube among highly TB exposed gold miners in 
South Africa. https://doi.org/10.17037/DATA.0000189110.




Due to ethical concerns, dataset access is restricted to ensure 
privacy and confidentiality of participant data. However, raw 
data is available upon request under a custom data sharing 
agreement and will require authorization from Principal Investi-
gators (Professor Violet Chihota: VChihota@auruminstitute.org 
and Professor Katherine Fielding: Katherine.Fielding@lshtm.
ac.uk). Once access is granted, the files will be made available 
on LSHTM Data Compass.
The data codebook and user guide are available under the terms 
of the Creative Commons Attribution 3.0 International license 
(CC-BY 3.0).
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Variable N TB2-TB1 >0.6 n (%)
Univariable analysis
Crude 
OR 95% CI p-value*
BCG Scar 0.39
Yes/indeterminate¥ 159 28 (17.6) 1
No 55 7 (12.7) 0.68 0.28-1.66
Transverse diameter of TST 
induration, mm** 0.33
<5 65 8 (12.3) 1
≥5 101 18 (17.8) 1.55 0.63 - 3.79
BMI, kg/m2 0.03
18.5-24.9 47 7 (14.9) 1
25-29.9 92 9 (9.8) 0.62 0.22 - 1.78
≥30 75 19 (25.3) 1.94 0.74 - 5.05
* P-value from the likelihood ratio test; ** n=166; ¥, n=4 indeterminate.
QFT-Plus, QuantiFERON-TB Gold-Plus; TST, tuberculin skin test; OR, odds ratio; CI confidence interval.
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Major comments:
The data analysed are from a subset of a larger parent study and the 304 participants 
available for direct comparison form only 1.8% of the 17,030 who consented to screening; 
and the study participants included in the analysis are all very highly exposed to Mtb over a 
long period. i.e. It is not clear if the study population is representative of other settings, or 
to what extent the results are generalisable.
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Minor comments:
Abstract: Typo 33 years of age? 
 
○
Study limitations: The statement that “it is unlikely that the LTBI status would change over a 
relatively short period of follow-up” does not justify the lack of confirmatory testing. 
 
○
Discussion: No TST information is included in the title, abstract or discussion, but is included 
in the methods and main results. Suggest TST information is either included in the title and 
abstract, and concordance/discordance with the IGRA tests is interpreted and discussed 
further, or TST is removed entirely from this manuscript. 
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The observation that TB2-TB1 was associated with BMI deserves further discussion. 
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Conclusion (abstract and main text): Here and elsewhere - suggest statements that “QFT-
Plus showed similar performance to QFT-GIT” should be revised to state that QFT-Plus 
showed high agreement with QFT-GIT, or qualified as per the Discussion “suggesting similar 
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